Coming off the success of its mRNA vaccine for COVID-19, Moderna announced on Dec. 13 that it achieved encouraging results when it turned its vaccine technology against cancer.The company reported in a release that among 157 people with stage 3 or stage 4 melanoma, a personalized cancer vaccine that Moderna developed with Merckcreated using mRNA genetic material from each patient's respective tumorsreduced the risk of recurrence or death by 44% compared to standard care.
[
add
]
[
|
|
...
]